Safety, pharmacokinetics, and preliminary efficacy of VS-01, an intraperitoneal liposomal infusion, in patients with decompensated liver cirrhosis, ascites, and covert hepatic encephalopathy: a phase 1b, first-in-human, open-label, non-randomised, single ascending and multiple dose study | Synapse
March 3, 2026Open Access
Safety, pharmacokinetics, and preliminary efficacy of VS-01, an intraperitoneal liposomal infusion, in patients with decompensated liver cirrhosis, ascites, and covert hepatic encephalopathy: a phase 1b, first-in-human, open-label, non-randomised, single ascending and multiple dose study
Key Points
Overall safety of VS-01 was observed among patients with decompensated liver cirrhosis and ascites, indicating feasibility.
The pharmacokinetics and preliminary efficacy of the liposomal infusion were promising in addressing hepatic encephalopathy.
This open-label, non-randomised trial analyzed single ascending and multiple doses of VS-01 for potential therapeutic effects.
Future studies should evaluate long-term outcomes to confirm efficacy and safety in diverse patient populations.